Chief Financial Officer
Education: MSc in Business Economics and Auditing, Executive Management Program, INSEAD
Background: Johnny Stilou has held numerous Executive positions as Chief Financial Officer within the biotech and pharmaceutical industry, most recently as CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen). Prior to Nuevolution, he served as CFO at Veloxis Pharmaceuticals until the company was acquired by Asahi Kasei.
Other ongoing assignments: None
Scandion Oncology shares and warrants
13.333 shares and 482.033 warrants.
Year of commencement of the position: 2021
Independence: Independent in relation to both the Company and larger shareholders